Labetuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Labetuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target carcinoembryonic antigen
Clinical data
Legal status ?
Identifiers
CAS number 219649-07-7 N
ATC code None
KEGG D08936 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1]

This drug was developed by Immunomedics, Inc.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.